Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of GLS-010 in recurrent or metastatic cervical cancer
CTR20190394Phase 2Active
- Sponsor
- Harbin Yuheng Pharmaceutical
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab in Cervical Cancer (CC), sponsored by Harbin Yuheng Pharmaceutical. Started Jun 2019; status: active.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20190394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190394.